Child Psychiatry and Human Development

, Volume 37, Issue 3, pp 241–253 | Cite as

Fluoxetine Monotherapy in Attention-Deficit/Hyperactivity Disorder and Comorbid Non-Bipolar Mood Disorders in Children and Adolescents

  • Humberto Quintana
  • Grant J. Butterbaugh
  • William Purnell
  • Ann K. Layman
Original Paper


Children with attention-deficit/hyperactivity disorder (ADHD) are at increased risk for developing comorbid non-bipolar mood disorders. Fluoxetine monotherapy is an established treatment for pediatric mood disorders; however its efficacy in ADHD and comorbid mood disorder is unknown. Therefore, we evaluated 30 children who met DSM-IV criteria for ADHD and comorbid non-bipolar mood disorders in a prospective, 6–12-week open-label, study of fluoxetine monotherapy. Fluoxetine was associated with significant decreases in the severity of depressive symptoms, and also, associated with significant decreases on subscales of inattention/overactivity and aggression/defiant symptoms—47% of participants were much or very much improved without observed adverse effects.


Fluoxetine Attention-deficit/hyperactivity disorder Mood disorders Children Adolescents 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



The authors are thankful to Eli Lilly for their support of this research through Grant ID # B1Y-MC-X143. We also want to thank the LSUHSC IRB that approved this study and that has encouraged our research in child and adolescent psychiatry.


  1. 1.
    American Psychiatric Association (1997) diagnostic and statistical manual of mental disorders, 4th edn (DSM-IV). American Psychiatric Association, Washington, DCGoogle Scholar
  2. 2.
    Cheung AH, Emslie GJ, Mayes TL (2005) Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 46:735–754PubMedCrossRefGoogle Scholar
  3. 3.
    Yorbik O, Birmaher B, Axelson D, Williamson DE, Ryan ND (2004) Clinical characteristics of depressive symptoms in adolescents with major depressive disorder. J Clin Psychiatry 65(12):1654–1659 (ISSN: 0160-6689)PubMedCrossRefGoogle Scholar
  4. 4.
    Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, Mennin D, Marrs A, Ouellette C, Moore P, Spencer T, Norman D, Wilens T, Kraus I, Perrin J (1996) A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 53:437–446PubMedGoogle Scholar
  5. 5.
    Barkley RA (1990) ADHD: a handbook for diagnosis and treatment. Guilford Press, New YorkGoogle Scholar
  6. 6.
    Pliszka SR (1987) Tricyclic antidepressants in the treatment of children with attention deficit disorder. J Am Acad Child Adolesc Psychiatry 26:127–132PubMedCrossRefGoogle Scholar
  7. 7.
    Hazell P, O’Connell D, Heathcote D, Robertson J, Henry D (1995) Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 310:897–901PubMedGoogle Scholar
  8. 8.
    Vitiello B, Swedo S (2004) Antidepressant medications in children. N Engl J Med 350:1489–1491PubMedCrossRefGoogle Scholar
  9. 9.
    Whittington CG, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E (2004) Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363:1341–1345PubMedCrossRefGoogle Scholar
  10. 10.
    Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J (1997) A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031–1037PubMedGoogle Scholar
  11. 11.
    Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG (2002) Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205–1215PubMedCrossRefGoogle Scholar
  12. 12.
    Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M (1991) Treatment of ADHD with fluoxetine: A preliminary trial. J Am Acad Child Adolesc Psychiatry 30:762–767PubMedCrossRefGoogle Scholar
  13. 13.
    Treatment for Adolescents with Depressions Study (TADS) Team (2004) Fluoxetine, cognitive-behavioral therapy and their combination for adolescents with depression. JAMA 292:807–820CrossRefGoogle Scholar
  14. 14.
    Hechtman L (2003) Clinical trial of Dexedrine, Paxil, and placebo for adult ADHD. AACAP Sci Proc 94Google Scholar
  15. 15.
    Weiss M, Hechtman L (2006). A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention- deficit/hyperactivity disorder. J Clin Psychiatry 67(4):611–619 (ISSN: 0160-6689)PubMedCrossRefGoogle Scholar
  16. 16.
    Gammon GD, Brown TE (1993) Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 3:1–10CrossRefPubMedGoogle Scholar
  17. 17.
    Findling R (1996) Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol 6:165–175PubMedGoogle Scholar
  18. 18.
    Teare M, Fistad MA, Weller EB, Weller RA, Salmon P (1998) Development and criterion validity of the Children’s Interview for Psychiatric Syndromes (ChIPS). J Child Adolesc Psychopharmacol 8:205–211PubMedGoogle Scholar
  19. 19.
    Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62PubMedCrossRefGoogle Scholar
  20. 20.
    Guy W (1976) ECDEU Assessment Manual for Psychopharmacology (DHEW Publication ADM 76-338). US Department of Health, Education, and Welfare, Rockville, MDGoogle Scholar
  21. 21.
    Conners CK (1973) Rating scales for use in drug studies with children. Psychopharmacol Bull 9:24–84Google Scholar
  22. 22.
    Loney J, Milich R (1982) Hyperactivity, inattention, and aggression in clinical practice. In: Wolraich M, Routh D (eds) Advances in developmental and behavioral pediatrics. vol 3, JAL, Greenwich CT, pp113–147Google Scholar
  23. 23.
    Barrickman L, Perry P, Allen AJ, Kuperman S, Arndt S, Herrmann K, Schumacher E (1995) Buproprion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:649–657PubMedCrossRefGoogle Scholar
  24. 24.
    Kutcher S, Reiter S, Gardner D (1995) Pharmacotherapy approaches and applications. In: March J (ed.), Anxiety disorders in children and adolescents. Guilford Press, New York, pp 341–385Google Scholar
  25. 25.
    Cook T, Campbell D (1979) Quasi-experimentation: design and analysis issues for field settings. Houghton Mifflin, BostonGoogle Scholar
  26. 26.
    Shaffer D, Guold MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S (1983) Children’s global assessment scale [CGAS]. Arch Gen Psychiatry 40:1228–1231PubMedGoogle Scholar
  27. 27.
    Bangs M, Petti T, Janus M-D (1994) Fluoxetine-induced memory impairment in an adolescent. J Am Acad Child Adolesc Psychiatry 33:1303–1306PubMedCrossRefGoogle Scholar
  28. 28.
    Nemeroff CB, DeVane CL, Pollack BG (1996) Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311–320PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Humberto Quintana
    • 1
  • Grant J. Butterbaugh
    • 1
  • William Purnell
    • 1
  • Ann K. Layman
    • 1
  1. 1.Department of PsychiatryLouisiana State University Health Sciences Center School of Medicine at New OrleansNew OrleansUSA

Personalised recommendations